No abstract

No abstract

No abstract

No abstract

cyclophosphamide/ifosfamide. DVSS scores and the presence of LUTD, defined as DVSS scores above gender-specific thresholds (males!9, females!6), were compared across cohorts.RESULTS: Median DVSS scores were higher in the study cohort (6 vs 4, p[0.003). Moreover, children in the study cohort were more likely to exceed threshold scores for LUTD (38.8% vs 21%, p[0.014; OR 1.8). Sub-analysis by gender revealed female cancer survivors are more likely to report LUTD than controls (57.5% vs 30%, p[0.013, OR 1.9), Figure . A post hoc analysis eliminating the DVSS "stress" domain (by removing 3 points from the stress domain for those who had responded affirmatively) was completed to control for the potential stressful impact of a cancer diagnosis. In this analysis, median DVSS sum scores remained significantly higher in the study cohort (4.5 vs 3, p[0.002). Similarly, even without the contribution of the stress domain, children in the study cohort were significantly more likely to exceed threshold scores for LUTD (27.5% vs 12.3%, p[0.016).CONCLUSIONS: Childhood cancer survivors who received VCR and/or DOX reported higher rates of LUTD than controls. Female cancer survivors appear more likely to report symptoms of LUTD than males. Further study with a positive control cohort of cancer survivors who received non-VCR, non-DOX chemotherapy is underway to elucidate the contribution of a cancer diagnosis to LUTD.